Both TP53 mutations and MSI-H were associated with a prolonged DFS in patients with 5-FU-based adjuvant treatment; however, in the multivariate analysis adjusted for tumor grade, histology, number of tumor-positive nodes, and depth of tumor invasion, only TP53 remained a statistically significant independent predictor of DFS [61]. Here, TP53 is linked to neoplasm.